PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.
PRINCIPAL DISPLAY PANEL - BOTTLE LABEL Description: Urelle tablets for oral administration are supplied as navy blue round tablets with "A-002" debossed on one side. Each Tablet Contains: Hyoscyamine Sulfate 0.12 mg Methenamine 81.0 mg Methylene Blue 10.8 mg Phenyl Salicylate 32.4 mg Sodium Phosphate Monobasic 40.8 mg Dosage: Adults - one tablet orally 4 times per day followed by liberal fluid intake. Pediatric - Dosage must be individualized by a physician for older children. Urelle is not recommended for use in children 6 years of age or younger. Precaution: Contains Methylene Blue and should NOT be taken with serotonergic psychiatric medications. For full product information please refer to www.jazzpharma.com. To report a serious adverse event or obtain product information, contact (800) 890 3098. Storage: Store at controlled room temperature 20-25C (68-77F). Dispense in a tight, light resistant container as defined in the USP. KEEP OUT OF THE REACH OF CHILDREN. 90 TABLETSNDC 66663-219-01 urelle Urinary Antiseptic Rx Only Dist. by: JAZZ PHARMACEUTICALS COMMERCIAL CORP. Philadelphia, PA 19103 Mfd. by: PureTek Corporation San Fernando, CA 91340 Urelle is a registered trademark of Jazz Pharmaceuticals. Note: Patients should be advised that urine will be colored blue when taking this medication. URLLt-12-02
INDICATIONS & USAGE SECTION.
Indications and Usage: Urelle is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.
DOSAGE & ADMINISTRATION SECTION.
Dosage and Administration: Adults One tablet orally 4 times per day followed by liberal fluid intake. Pediatric Dosage must be individualized by a physician for older children. Urelle is not recommended for use in children 6 years of age or younger.
HOW SUPPLIED SECTION.
How Supplied: Urelle tablets for oral administration are supplied in child resistant bottles of 90 tablets (NDC 66663-219-01). Store at controlled room temperature 20-25C (68-77F). Dispense in a tight, light resistant container as defined in the USP. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. Distributed by: JAZZ PHARMACEUTICALS COMMERCIAL CORP. Philadelphia, PA 19103 www.jazzpharma.com Manufactured by: PureTek Corporation. San Fernando, CA 91340 Urelle is a registered trademark of Jazz Pharmaceuticals. To report a serious adverse event or obtain product information, contact (800) 890 3098. Rx Only URLLw-12-01
Description: Urelle tablets for oral administration are supplied as navy blue round tablets with A-002 debossed on one side. Each Tablet Contains: Hyoscyamine Sulfate 0.12 mg Methenamine 81.0 mg Methylene Blue 10.8 mg Phenyl Salicylate 32.4 mg Sodium Phosphate Monobasic 40.8 mg
Precautions: Cross sensitivity and/or related problems- patients intolerant of belladonna alkaloids or salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers. Urelle contains methylene blue. Methylene blue should generally NOT be given to patients taking serotonergic drugs. Drug Interactions: Although the exact mechanism of this drug interaction is unknown, methylene blue inhibits the action of monoamine oxidase A an enzyme responsible for breaking down serotonin in the brain. It is believed that when methylene blue is given to patients taking serotonergic psychiatric medications, high levels of serotonin can build up in the brain, causing toxicity. This is referred to as Serotonin Syndrome. Signs and symptoms of Serotonin Syndrome include mental changes (confusion, hyperactivity, memory problems), muscle twitching, excessive sweating, shivering or shaking, diarrhea, trouble with coordination, and/or fever. Additional Information for Healthcare Professionals: Methylene blue can interact with serotonergic psychiatric medications and cause serious CNS toxicity. In emergency situations requiring life-threatening or urgent treatment with methylene blue (as described above), the availability of alternative interventions should be considered and the benefit of methylene blue treatment should be weighed against the risk of serotonin toxicity. If methylene blue must be administered to a patient receiving a serotonergic drug, the serotonergic drug must be immediately stopped, and the patient should be closely monitored for emergent symptoms of CNS toxicity for two weeks (five weeks if fluoxetine [Prozac] was taken), or until 24 hours after the last dose of methylene blue, whichever comes first. In non-emergency situations when non-urgent treatment with methylene blue is contemplated and planned, the serotonergic psychiatric medication should be stopped to allow its activity in the brain to dissipate. Most serotonergic psychiatric drugs should be stopped at least 2 weeks in advance of methylene blue treatment. Fluoxetine (Prozac), which has a longer half-life compared to similar drugs, should be stopped at least 5 weeks in advance. Treatment with the serotonergic psychiatric medication may be resumed 24 hours after the last dose of methylene blue. Serotonergic psychiatric medications should not be started in a patient receiving methylene blue. Wait until 24 hours after the last dose of methylene blue before starting the antidepressant. Educate your patients to recognize the symptoms of serotonin toxicity or CNS toxicity and advise them to contact a healthcare professional immediately if they experience any symptoms while taking serotonergic psychiatric medications or methylene blue. Report adverse events involving methylene blue to the FDA MedWatch program by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For more information on Urelle, call 877 329 2256.
CLINICAL PHARMACOLOGY SECTION.
Inactive Ingredients: Corn Starch, Dicalcium Phosphate, FD&C Blue #2/Indigo Carmine Aluminum Lake, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polyvinyl Alcohol, Talc, Titanium Dioxide.
Contraindications: Hypersensitivity to any of the ingredients is possible. Risk - benefit should be carefully considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).
Warnings: If rapid pulse, dizziness, or blurring of vision occurs, discontinue use immediately. Patients should be advised that urine will be colored blue when taking this medication. Do not exceed recommended dosage.